Mogamulizumab
Mogamulizumab is an antibody that clears cancerous T cells from the blood in mycosis fungoides and Sézary syndrome, the leukaemic form of skin lymphoma.
MAVORIC (2018): PFS 7.7 vs 3.1 months versus vorinostat, with the best responses in blood compartment and Sézary syndrome. Approved in Japan (2012) for ATLL and CCR4+ PTCL/CTCL; US/EU 2018 for MF/SS after one systemic therapy. Rash (mogamulizumab-associated rash) and increased GVHD risk after subsequent allogeneic transplant.
- Medicare
- Part B (clinician-administered)
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies.
- Commercial insurance
- covered with prior authorisation
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
- Notes
- TA577 (2019) appraised mogamulizumab for mycosis fungoides and Sézary syndrome; outcome not verified here. Check NICE.
Sources: NICE search: mogamulizumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| JP | 2012 | Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL |
| US | 2018 | Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy |
| EU | 2018 | MF/SS after ≥1 systemic therapy |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Mogamulizumab" OR ABSTRACT:"Mogamulizumab" OR TITLE:"Poteligeo" OR ABSTRACT:"Poteligeo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mogamulizumab, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD52
Shares ADCC (antibody-dependent cellular cytotoxicity), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Monoclonal antibodies and the tag gap-fill.
- ProductElotuzumab
Shares ADCC (antibody-dependent cellular cytotoxicity), Monoclonal antibodies and the tag gap-fill.
- ProductPralatrexate
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.
- ProductBelinostat
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.
- ProductRomidepsin
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.
- TargetCD7
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.
- ProductDuvelisib
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.
- ProductAsparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag gap-fill.